FINNENCE▪
00:00:00 UTCSYS ONLINE
FINNENCE ▪ THE WIRE FILE

THE WIRE · № 80260

News■ Unclear/unknown

Paradigm Therapeutics, Inc. nominada al prestigioso premio Prix Galien USA 2026 "Best Start-Up"

Paradigm Therapeutics, Inc. nominada al prestigioso premio Prix Galien USA 2026 "Best Start-Up"
EXHIBIT · mmx.prnewswire.com
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

Award nomination for a topical EB therapy is a private biotech milestone with no public ticker exposure.

Private biotech recognition, no tradable link
CATALYST TO WATCH

Regulatory decision on SD-101

MAIN RISK

Nomination does not imply approval

FULL DISPATCH

-Paradigm Therapeutics, Inc. ha sido nominada por segundo año consecutivo al prestigioso premio Prix Galien USA 2026 "Best Start-Up" por SD-101 (Zorblesia™), una terapia tópica para tratar toda la superficie cutánea de pacientes con epidermólisis bullosa (EB) SD-101 (Zorblesia™) es la...

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

AFFECTEDHealthcare

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED
№ 01prnewswireprnewswire.com · PRIMARY2026-10-14 15:58 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.